Literature DB >> 10543617

High-titer recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H.

X Zhang1, M De Alwis, S L Hart, F W Fitzke, S C Inglis, M E Boursnell, R J Levinsky, C Kinnon, R R Ali, A J Thrasher.   

Abstract

Production of high-titer rAAV is essential for in vivo clinical application. One limiting factor may be the failure of existing systems to replicate the packaging genome in such a way that expression of Rep and Cap proteins is coordinately amplified. DISC-HSV (disabled single-cycle virus) is a genetically modified herpes simplex virus (HSV) that by deletion of glycoprotein H (gH) is infectious only if propagated in a complementing cell line. In this study, we have used DISC-HSV as a helper for rAAV replication, and have simulated to some extent the amplication of the rep and cap genomes seen in wtAAV infection by incorporating both these and vector sequences in HSV amplicons. Facilitated production of AAV Rep and Cap proteins translates into a considerably improved recovery of rAAV, which transduces cells of the neuroretina in vivo with high efficiency. The potential for contamination with infectious herpes particles is eliminated by the use of noncomplementing (gH-) cell lines to propagate the virus, and by standard purification methods. The use of DISC-HSV and herpes-derived amplicons for production of rAAV may be a useful strategy for future in vivo studies and for clinical application.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543617     DOI: 10.1089/10430349950016861

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

1.  Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells.

Authors:  Xinping Fu; Armando Rivera; Lihua Tao; Bart De Geest; Xiaoliu Zhang
Journal:  Mol Ther       Date:  2011-12-06       Impact factor: 11.454

Review 2.  Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies.

Authors:  Nathalie Clément; David R Knop; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

Review 3.  Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.

Authors:  Tamas Virag; Sylvain Cecchini; Robert M Kotin
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

4.  Novel strategy for generation and titration of recombinant adeno-associated virus vectors.

Authors:  Ai-Li Shiau; Pu-Ste Liu; Chao-Liang Wu
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.

Authors:  Mei Hong Tan; Alexander J Smith; Basil Pawlyk; Xiaoyun Xu; Xiaoqing Liu; James B Bainbridge; Mark Basche; Jenny McIntosh; Hoai Viet Tran; Amit Nathwani; Tiansen Li; Robin R Ali
Journal:  Hum Mol Genet       Date:  2009-03-19       Impact factor: 6.150

6.  In vivo imaging of microscopic structures in the rat retina.

Authors:  Ying Geng; Kenneth P Greenberg; Robert Wolfe; Daniel C Gray; Jennifer J Hunter; Alfredo Dubra; John G Flannery; David R Williams; Jason Porter
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-02       Impact factor: 4.799

7.  Replication competent helper functions for recombinant AAV vector generation.

Authors:  L Cao; M During; W Xiao
Journal:  Gene Ther       Date:  2002-09       Impact factor: 5.250

Review 8.  Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown.

Authors:  Aziz Alami Chentoufi; Elizabeth Kritzer; David M Yu; Anthony B Nesburn; Lbachir Benmohamed
Journal:  Clin Dev Immunol       Date:  2012-03-26

9.  Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy.

Authors:  Divya Ravirala; Brandon Mistretta; Preethi H Gunaratne; Guangsheng Pei; Zhongming Zhao; Xiaoliu Zhang
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.